Form 4 · AMGN
Amgen director David W. Gibbs reports an award of 278 shares
Part of a grouped insider digest: see all related filings with totals →
David W. Gibbs, an Amgen director, filed a Form 4 on Nov 9, 2026 at 7:44 PM ET reporting transactions on Nov 6, 2026.
The filing reports 278 shares in a grant or award (code A).
After these transactions, the filing lists 278 shares held directly.
Effect on holdings
David W. Gibbs reported no directly held shares before these transactions, according to the filing's own figures.
Reporting person
- David W. Gibbs, director (as filed: Gibbs David W)
Transactions as reported
| Date | Code | Security | Shares | Price | Acquired or disposed | Held after | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-11-06 | A | Common Stock | 278 | Acquired | 278 | Direct |
Codes: P purchase, S sale, A grant or award, M/X/C exercise or conversion, F shares withheld for taxes or the exercise price, G gift. Prices are as reported; some are weighted averages of several trades.
Source
- Form 4 filed Nov 9, 2026 (document)
- Filing index on SEC EDGAR (all documents and exhibits)
Amgen company file → · More Amgen filings
Disclosures
- Editor holdings in AMGN
- The editor holds no position in Amgen (AMGN). As of Nov 11, 2026.
- Last updated
- Nov 10, 2026
A summary of a public filing for general education, the same for every reader. Not a recommendation to buy, sell or hold AMGN.